Bibliographic Details
| Title: |
Probenecid as a pharmacotherapy for alcohol use disorder: A randomized placebo‐controlled alcohol interaction trial. |
| Authors: |
Hornbacher, Rivkah, Gully, Brian J., Brown, Zoe E., Brown, Joshua C., Magill, Molly, Cioe, Patricia A., Swift, Robert M., Sanna, Pietro Paolo, Haass‐Koffler, Carolina L. |
| Source: |
Alcohol, Clinical & Experimental Research; Dec2024, Vol. 48 Issue 12, p2391-2403, 13p |
| Subject Terms: |
RODENTS, SELF-evaluation, DRUG allergy, RESEARCH funding, PLACEBOS, ALCOHOLIC intoxication, COGNITIVE testing, FOOD consumption, CELL membranes, PATIENT safety, BLOOD testing, STATISTICAL sampling, BLIND experiment, ETHANOL, METHOTREXATE, QUESTIONNAIRES, TREATMENT effectiveness, RANDOMIZED controlled trials, DESCRIPTIVE statistics, PROBENECID (Drug), CROSSOVER trials, DESIRE, ELECTROCARDIOGRAPHY, MOLECULAR structure, URINALYSIS, ALCOHOLISM, ALCOHOL drinking, DRUG development, PSYCHOLOGICAL tests, MEDICAL screening, COMPARATIVE studies, BIOMARKERS, PENICILLIN |
| Abstract: |
Background: This study shows the first evidence for pannexin 1 channels as a new target to develop medications for alcohol use disorder (AUD). Due to its history of long‐term safe clinical use and preclinical evidence of reducing excessive alcohol intake in rodents, probenecid has clinical potential for AUD. Methods: We conducted a Phase I/IIa randomized, double‐blind, placebo‐controlled, crossover trial investigating the safety, tolerability, and efficacy of an oral dose of probenecid (2 g) when administered with alcohol (0.08 g/dL) in individuals who regularly consume alcohol to the 0.08 g/dL level (N = 35) and in individuals with mild to severe AUD. Alcohol pharmacokinetics and subjective responses were evaluated to assess potential interactions between probenecid and alcohol. Alcohol craving, inflammatory biomarkers, cognitive assessments, and hemodynamics were assessed as additional alcohol research domains. All outcomes were assessed both in the ascending and descending limb of alcohol intoxication using Generalized Estimating Equation. Results: Probenecid did not exert any significant effect on alcohol pharmacokinetics and did not affect alcohol stimulation or sedation. Probenecid, compared to placebo, significantly decreased alcohol craving during the alcohol ascending limb. Inflammatory biomarkers, cognitive performance following alcohol ingestion, and hemodynamics were likewise not affected by probenecid administration. Analysis of sex as a biological variable revealed no differences of probenecid compared to placebo. Conclusions: Taken together, our data support the potential of probenecid for treatment of AUD and suggest that pannexin 1 channels represent a novel emerging therapeutic target for the development of new pharmacotherapies for treating AUD. [ABSTRACT FROM AUTHOR] |
|
Copyright of Alcohol, Clinical & Experimental Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
